CorMedix rises on Q2 revenue beat

CorMedix

13/08/2026 13:03

** Shares of biopharma firm CorMedix CRMD.O rise 3.8% to $12.06 premarket
** Co reports Q2 revenue of $101.93 million, beating analysts' average estimate of $95.62 million, according to LSEG compiled data
** Co posts Q2 profit of 29 cents, vs estimates of 24 cents
** As of last close, CRMD stock was down ~39% YTD 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com))